| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/21/2000 | WO2000054604A1 Method of using anti-phospholipase a2 antibodies to enhance growth or improve feed efficiency |
| 09/21/2000 | WO2000054583A1 Methods for culturing fluid-filled sensory organs |
| 09/21/2000 | WO2000040716A3 Soluble receptor br43x2 and methods of using them for therapy |
| 09/21/2000 | WO2000040225A3 Inhibition of tnf activity |
| 09/21/2000 | WO2000039292A3 Antisense oligonucleotide for inhibiting the expression of the adhesion molecule very late antigen 4 (vla-4) in human cells |
| 09/21/2000 | WO2000039154A3 Peptides of the at1 receptor and their use for preeclampsia and malign hypertension |
| 09/21/2000 | WO2000027868A3 Connective tissue growth factor (ctgf) and methods of use |
| 09/21/2000 | WO2000027207A8 Compositions of restricted cells capable of rapid growth which produce proliferation suppressive materials, and uses thereof |
| 09/21/2000 | WO2000027193A9 Method for treating a patient with neoplasia by treatment with a gonadotropin releasing hormone analog |
| 09/21/2000 | WO2000026340A9 Novel nucleic acid molecules encoding opioid growth factor receptors |
| 09/21/2000 | WO2000026242A3 Dna replication-regulating genes, antibodies thereto and diagnostic applications thereof |
| 09/21/2000 | WO2000026227A9 Ldl related protein and uses thereof |
| 09/21/2000 | WO2000022001A3 A potassium channel of the erg family |
| 09/21/2000 | WO2000021560A9 Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY |
| 09/21/2000 | WO2000021550A8 Methods and compositions for treating neurodegenerative diseases |
| 09/21/2000 | WO2000020598A9 Peptides useful for reducing symptoms of toxic shock syndrome and septic shock |
| 09/21/2000 | WO2000018783A9 Mammaglobin, a secreted mammary-specific breast cancer protein |
| 09/21/2000 | WO2000017334A3 Analysis of ligand activated nuclear receptors i(in vivo) |
| 09/21/2000 | WO2000015792A3 Promotion or inhibition of angiogenesis and cardiovascularization |
| 09/21/2000 | WO2000010602A9 Lats knock-out animal models and their uses |
| 09/21/2000 | WO1999065329A8 Dietary supplement containing colostrinin |
| 09/21/2000 | WO1999064378A3 Directed combinatorial compound library and high throughput assays for screening same |
| 09/21/2000 | DE19910108A1 Zellen, die ein Amyloidvorläuferprotein und eine alpha-Sekretase coexprimieren, ein Testverfahren zur Identifikation alpha-Sekretase-aktiver Substanzen sowie eines zur Identifikation weiterer Sekretasen, ein Testverfahren zur Bestimmung der Anfälligkeit gegenüber Morbus Alzheimer und Verwendung von Nukleinsäuren, die für eine alpha-Sekretase codieren, für die Gentherapie Cells, which co-express an amyloid precursor protein and an alpha-secretase, a test method for identifying alpha-secretase active substances as well as one further for identifying secretases, a test method for determining the susceptibility to Alzheimer's disease, and use of nucleic acids encoding an alpha-secretase , for gene therapy |
| 09/21/2000 | DE10012095A1 Treatment of diabetes mellitus using mixture of enzymes having lipolytic, proteolytic and amylolytic activity, e.g. pancreatin, regulates glycemia and also reduces post-complications |
| 09/21/2000 | CA2369319A1 Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators |
| 09/21/2000 | CA2368150A1 1-acyl-7-nitroindoline derivatives, their preparation and their use as photocleavable precursors |
| 09/21/2000 | CA2368068A1 27 human secreted proteins |
| 09/21/2000 | CA2367917A1 Bacterial membrane fractions with adjuvant effect |
| 09/21/2000 | CA2367906A1 Tcl-1b gene and protein and related methods and compositions |
| 09/21/2000 | CA2367862A1 Gamma-ketoacid dipeptides as inhibitors of caspase-3 |
| 09/21/2000 | CA2367643A1 Ocular therapy in keratoconjuctivitis sicca using topically applied androgens or tgf-.beta. |
| 09/21/2000 | CA2367611A1 Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis |
| 09/21/2000 | CA2367447A1 Treatment of asthma |
| 09/21/2000 | CA2367375A1 Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| 09/21/2000 | CA2367340A1 Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
| 09/21/2000 | CA2367256A1 Surface localized colligin/hsp47 in carcinoma cells |
| 09/21/2000 | CA2367247A1 Compositions and methods of use of ldl-like receptor ligands for the treatment of cancer and angiogenic-based disease |
| 09/21/2000 | CA2367213A1 Novel antiangiogenic peptides |
| 09/21/2000 | CA2367211A1 Immunostimulant bacterial membrane fractions in cancer treatment |
| 09/21/2000 | CA2366195A1 Human pancreas and pancreatic cancer associated gene sequences and polypeptides |
| 09/21/2000 | CA2366174A1 Human colon cancer associated gene sequences and polypeptides |
| 09/21/2000 | CA2366130A1 Human cancer associated gene sequences and polypeptides |
| 09/21/2000 | CA2365451A1 Nucleic acid molecule comprising a nucleic acid sequence coding for a hemocyanin |
| 09/21/2000 | CA2365214A1 Vertebrate protein slit, dna sequence encoding it and uses thereof |
| 09/21/2000 | CA2365096A1 Polyunsaturated fatty acid (pufa) elongase from caenorhabditis elegans |
| 09/21/2000 | CA2364941A1 Novel protein and its use |
| 09/21/2000 | CA2364739A1 Regulators of intracellular phosphorylation |
| 09/21/2000 | CA2364650A1 50 human secreted proteins |
| 09/21/2000 | CA2364637A1 50 human secreted proteins |
| 09/21/2000 | CA2364635A1 47 human secreted proteins |
| 09/21/2000 | CA2364630A1 50 human secreted proteins |
| 09/21/2000 | CA2364629A1 Human lung cancer associated gene sequences and polypeptides |
| 09/21/2000 | CA2364590A1 Human prostate cancer associated gene sequences and polypeptides |
| 09/21/2000 | CA2364568A1 Method for refolding molecules of polypeptides containing ig domains |
| 09/21/2000 | CA2364549A1 50 human secreted proteins |
| 09/21/2000 | CA2363496A1 Differential expression of organellar gene products |
| 09/21/2000 | CA2363024A1 Interleukin 17 receptor-like protein |
| 09/21/2000 | CA2363022A1 49 human secreted proteins |
| 09/21/2000 | CA2363019A1 49 human secreted proteins |
| 09/21/2000 | CA2361939A1 Modified amino acid amides, pharmaceutical compositions containing these compounds and processes for preparing them |
| 09/21/2000 | CA2361289A1 Compositions for promoting nerve regeneration |
| 09/21/2000 | CA2361277A1 49 human secreted proteins |
| 09/20/2000 | EP1036798A1 Peptides having anti-cell adhesion activity |
| 09/20/2000 | EP1036566A1 Preparation for continuous intravenous administration |
| 09/20/2000 | EP1036561A1 Buccal, non-polar spray |
| 09/20/2000 | EP1036188A1 ribG |
| 09/20/2000 | EP1036179A1 Method for preparing polypeptides with appropriate glycosilation |
| 09/20/2000 | EP1036178A1 Identification of lysolipid receptors involved in inflammatory response |
| 09/20/2000 | EP1036175A1 Human brain derived kcnq2 potassium channel |
| 09/20/2000 | EP1036174A2 Novel peptide, apoep1.b, compositions and uses thereof |
| 09/20/2000 | EP1036173A2 Methods and means for inducing apoptosis by interfering with bip-like proteins |
| 09/20/2000 | EP1036172A1 SEQUENCES CODING FOR kin17 PROTEIN AND THEIR APPLICATIONS |
| 09/20/2000 | EP1036171A2 Molecules interacting with apoptin |
| 09/20/2000 | EP1036168A1 Purification and microsequencing of hyaluronidase isozymes |
| 09/20/2000 | EP1036167A2 Nuclear targeting by means of streptococcal protein h |
| 09/20/2000 | EP1036165A1 Human rnase h and compositions and uses thereof |
| 09/20/2000 | EP1036164A1 Chemokine alpha-5 |
| 09/20/2000 | EP1036163A1 Differentiation of adipose stromal cells into osteoblasts and uses thereof |
| 09/20/2000 | EP1036162A1 Engraftable neural progenitor and stem cells for brain tumor therapy |
| 09/20/2000 | EP1036095A1 Oxygen-transporting albumin-based blood replacement composition and blood volume expander |
| 09/20/2000 | EP1036094A1 Cyp7 promoter-binding factors |
| 09/20/2000 | EP1036093A1 Conjugates useful in the treatment of prostate cancer |
| 09/20/2000 | EP1036092A2 Hydrophobically-modified protein compositions and methods |
| 09/20/2000 | EP1036091A1 5t4 tumour-associated antigen for use in tumour immunotherapy |
| 09/20/2000 | EP1036090A1 Echinocandin derivatives, preparation method and application as anti-fungal agents |
| 09/20/2000 | EP1036089A1 Wound healing compositions |
| 09/20/2000 | EP1036087A1 Secreted proteins and polynucleotides encoding them |
| 09/20/2000 | EP1036086A1 Caspase-14 polypeptides |
| 09/20/2000 | EP1036061A1 New compounds |
| 09/20/2000 | EP1036057A1 Radio-opaque polymer biomaterials |
| 09/20/2000 | EP1035870A1 Compositions and methods for treatment of hepatitis c virus-associated diseases |
| 09/20/2000 | EP1035868A1 Use of a fibrinogen receptor-antagonist for preventing disseminated intravascular coagulation |
| 09/20/2000 | EP1035866A2 Mixed lipopeptide micelles for inducing an immune response and their therapeutic uses |
| 09/20/2000 | EP1035865A2 Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination |
| 09/20/2000 | EP1035862A2 Cyclosporin-containing microemulsion preconcentrate composition |
| 09/20/2000 | EP1035861A1 Threonine-containing protegrins |
| 09/20/2000 | EP1035857A1 Oral antioxidant preparation comprising selenium and reduced glutathione |
| 09/20/2000 | EP1035856A1 Isolated dna encoding human h3 histamine receptor |
| 09/20/2000 | EP1035845A1 Modulators of cysteine protease |
| 09/20/2000 | EP1035836A1 Improved method for avoiding the degradation of an active principle |